Lisuride - axxonis

Drug Profile

Lisuride - axxonis

Alternative Names: Lisuride - subcutaneous; Lisuride - transdermal; Lisuride maleate; Lisuride Sub Q; Lisuride TDS; Lysuride; Nenad

Latest Information Update: 19 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer axxonis Pharma
  • Class Antimigraines; Antiparkinsonians; Ergolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Restless legs syndrome
  • No development reported Parkinson's disease

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 18 Feb 2010 Lisuride is still in preregistration stage for Parkinson's disease in Switzerland
  • 07 Jan 2010 Suspended - Preregistration for Restless legs syndrome in European Union (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top